TY - GEN
T1 - Extended release of dexamethasone from PLA/PLGA nanoparticles modified with a cationic surfactant
AU - Mulia, Kamarza
AU - Geraldine, Vanessa
AU - Krisanti, Elsa Anisa
N1 - Funding Information:
This research was funded by the Universitas Indonesia PUTI research scheme 1077/UN2.RST/HKP.05.00/2020.
Publisher Copyright:
© 2021 Author(s).
PY - 2021/3/23
Y1 - 2021/3/23
N2 - Long-term drug release is needed to treat ocular diseases, especially in the posterior region where the retina is located. Dexamethasone, an anti-inflammation drug, was encapsulated in biocompatible and biodegradable polylactic acid/polylactic-co-glycolic acid (PLA, PLGA 90:10, PLGA 50:50) nanoparticles prepared using the solvent evaporation method. The surface of the nanoparticles was modified with didodecyldimethylammonium bromide (DDAB), a cationic surfactant, to increase the residence time in the vitreous, by contacting the nanoparticles with various surfactant solutions (PVA, DDAB-1%, PVA-DDAB-0.5%, PVA-DDAB-1%). Those modified using DDAB-1% solution exhibit the highest positive zeta potential (52.7±9.3 mV) and the smallest particle size (329±44 nm). Dexamethasone released into a buffer release media (45°C, 100 rpm) from nanoparticles with higher lactic acid content (PLA and PLGA 90:10) showed zero- order release profile up to 48 days with 30-70% accumulative release. On the other hand, the DDAB release profiles show that after 6-12 days, the cationic surfactant was detached from the surface of the nanoparticles.
AB - Long-term drug release is needed to treat ocular diseases, especially in the posterior region where the retina is located. Dexamethasone, an anti-inflammation drug, was encapsulated in biocompatible and biodegradable polylactic acid/polylactic-co-glycolic acid (PLA, PLGA 90:10, PLGA 50:50) nanoparticles prepared using the solvent evaporation method. The surface of the nanoparticles was modified with didodecyldimethylammonium bromide (DDAB), a cationic surfactant, to increase the residence time in the vitreous, by contacting the nanoparticles with various surfactant solutions (PVA, DDAB-1%, PVA-DDAB-0.5%, PVA-DDAB-1%). Those modified using DDAB-1% solution exhibit the highest positive zeta potential (52.7±9.3 mV) and the smallest particle size (329±44 nm). Dexamethasone released into a buffer release media (45°C, 100 rpm) from nanoparticles with higher lactic acid content (PLA and PLGA 90:10) showed zero- order release profile up to 48 days with 30-70% accumulative release. On the other hand, the DDAB release profiles show that after 6-12 days, the cationic surfactant was detached from the surface of the nanoparticles.
UR - http://www.scopus.com/inward/record.url?scp=85103506440&partnerID=8YFLogxK
U2 - 10.1063/5.0047483
DO - 10.1063/5.0047483
M3 - Conference contribution
AN - SCOPUS:85103506440
T3 - AIP Conference Proceedings
BT - 5th Biomedical Engineering''s Recent Progress in Biomaterials, Drugs Development, and Medical Devices
A2 - Lischer, Kenny
A2 - Supriadi, Sugeng
A2 - Rahman, Siti Fauziyah
A2 - Whulanza, Yudan
PB - American Institute of Physics Inc.
T2 - 5th International Symposium of Biomedical Engineering, ISBE 2020
Y2 - 28 July 2020 through 29 July 2020
ER -